Parkinson disease genetics: A “continuum” from mendelian to multifactorial inheritance

Current Molecular Medicine

Volumn 14, Issue 8, 2014, Pages 1079-1088

  Petrucci, S ^a,b   Consoli, F ^a   Valente, E M ^a,c  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF SALERNO   (Italy)

Author keywords

Genetics; Monogenic; Multifactorial; Parkinson disease; Parkinsonism; Risk factor

Indexed keywords

ALPHA SYNUCLEIN; LEUCINE RICH REPEAT KINASE 2;

ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; BRAIN ATROPHY; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENVIRONMENTAL FACTOR; FRAGILE X SYNDROME; GENE MUTATION; GENETIC ANALYSIS; GENETIC SUSCEPTIBILITY; HUMAN; MENDELIAN RANDOMIZATION ANALYSIS; MULTIFACTORIAL INHERITANCE; PARKINSON DISEASE; POINT MUTATION; RISK FACTOR;

EID: 84911464006     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/1566524014666141010155509     Document Type: Article

References (112)

1. De Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006; 5(6): 525-35.
2. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003; 39(6): 889-909.
3. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24(2): 197-211.
4. Bonifati V, Fabrizio E, Vanacore N, De Mari M, Meco G. Familial Parkinson's disease: a clinical genetic analysis. Can J Neurol Sci 1995; 22(4): 272-9.
5. Lesage S, Brice A. Role of mendelian genes in "sporadic" Parkinson's disease. Parkinsonism Relat Disord 2012; 18 Suppl 1: S66-70.
6. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998; 392(6676): 605-8.
7. Valente EM, Abou-Sleiman PM, Caputo V, et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004; 304(5674): 1158-60.
8. Bonifati V, Rizzu P, van Baren Mj, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003; 299(5604): 256-9.
9. Edvardson S, Cinnamon Y, Ta-Shma A, et al. A deleterious mutation in DNAJC6 encoding the neuronal-specific clathrin-uncoating co-chaperone auxilin, is associated with juvenile parkinsonism. PLoS One 2012; 7(5): e36458.
10. Koroglu C, Baysal L, Cetinkaya M, Karasoy H, Tolun A. DNAJC6 is responsible for juvenile parkinsonism with phenotypic variability. Parkinsonism Relat Disord 2013; 19(3): 320-4.
11. Quadri M, Fang M, Picillo M, et al. Mutation in the SYNJ1 Gene Associated with Autosomal Recessive, Early-Onset Parkinsonism. Hum Mutat 2013; 34(9): 1208-15.
12. Krebs CE, Karkheiran S, Powell JC, et al. The Sac1 Domain of SYNJ1 Identified Mutated in a Family with Early-Onset Progressive Parkinsonism with Generalized Seizures. Hum Mutat 2013; 34(9): 1200-7.
13. Puschmann A. Monogenic Parkinson's disease and parkinsonism: clinical phenotypes and frequencies of known mutations. Parkinsonism Relat Disord 2013; 19(4): 407-15.
14. Crosiers D, Theuns J, Cras P, Van Broeckhoven C. Parkinson disease: insights in clinical, genetic and pathological features of monogenic disease subtypes. J Chem Neuroanat 2011; 42(2): 131-41.
15. Samaranch L, Lorenzo-Betancor O, Arbelo JM, et al. PINK1-linked parkinsonism is associated with Lewy body pathology. Brain 2010; 133(Pt 4): 1128-42.
16. Lohmann E, Thobois S, Lesage S, et al. A multidisciplinary study of patients with early-onset PD with and without parkin mutations. Neurology 2009; 72(2): 110-6.
17. Ephraty L, Porat O, Israeli D, et al. Neuropsychiatric and cognitive features in autosomal-recessive early parkinsonism due to PINK1 mutations. Mov Disord 2007; 22(4): 566-9.
18. Dekker M, Bonifati V, van Swieten J, et al. Clinical features and neuroimaging of PARK7-linked parkinsonism. Mov Disord 2003; 18(7): 751-7.
19. Abou-Sleiman pM, Healy DG, Wood NW. Causes of Parkinson's disease: genetics of DJ-1. Cell Tissue Res 2004; 318(1): 185-8.
20. Williams DR, Hadeed A, al-Din AS, Wreikat AL, Lees AJ. Kufor Rakeb disease: autosomal recessive, levodopa-responsive parkinsonism with pyramidal degeneration, supranuclear gaze palsy, and dementia. Mov Disord 2005; 20(10): 1264-71.
21. Ramirez A, Heimbach A, Grundemann J, et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 2006; 38(10): 1184-91.
22. Eiberg H, Hansen L, Korbo L, et al. Novel mutation in ATP13A2 widens the spectrum of Kufor-Rakeb syndrome (PARK9). Clin Genet 2012; 82(3): 256-63.
23. Bras J, Verloes A, Schneider Sa, Mole SE, Guerreiro RJ. Mutation of the parkinsonism gene ATP13A2 causes neuronal ceroid-lipofuscinosis. Hum Mol Genet 2012; 21(12): 2646-50.
24. Djarmati A, Hagenah J, Reetz K, et al. ATP13A2 variants in early-onset Parkinson's disease patients and controls. Mov Disord 2009; 24(14): 2104-11.
25. Yoshino H, Tomiyama H, Tachibana N, et al. Phenotypic spectrum of patients with PLA2G6 mutation and PARK14-linked parkinsonism. Neurology 2010; 75(15): 1356-61.
26. Di Fonzo A, Dekker MC, Montagna P, et al. FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome. Neurology 2009; 72(3): 240-5.
27. Sundal C, Fujioka S, Uitti RJ, Wszolek ZK. Autosomal dominant Parkinson's disease. Parkinsonism Relat Disord 2012; 18 Suppl 1: S7-10.
28. Houlden H, Singleton AB. The genetics and neuropathology of Parkinson's disease. Acta Neuropathol 2012; 124(3): 325-38.
29. Wider C, Skipper L, Solida A, et al. Autosomal dominant dopa-responsive parkinsonism in a multigenerational Swiss family. Parkinsonism Relat Disord 2008; 14(6): 465-70.
30. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276(5321): 2045-7.
31. Papadimitriou A, Veletza V, Hadjigeorgiou GM, Patrikiou A, Hirano M, Anastasopoulos I. Mutated alpha-synuclein gene in two Greek kindreds with familial PD: incomplete penetrance? Neurology 1999; 52(3): 651-4.
32. Spira PJ, Sharpe DM, Halliday G, Cavanagh J, Nicholson GA. Clinical and pathological features of a Parkinsonian syndrome in a family with an Ala53Thr alpha-synuclein mutation. Ann Neurol 2001; 49(3): 313-9.
33. Ki CS, Stavrou EF, Davanos N, et al. The Ala53Thr mutation in the alpha-synuclein gene in a Korean family with Parkinson disease. Clin Genet 2007; 71(5): 471-3.
34. Puschmann A, Ross OA, Vilarino-Guell C, et al. A Swedish family with de novo alpha-synuclein A53T mutation: evidence for early cortical dysfunction. Parkinsonism Relat Disord 2009; 15(9): 627-32.
35. Michell aW, Barker RA, Raha SK, Raha-Chowdhury R. A case of late onset sporadic Parkinson's disease with an A53T mutation in alpha-synuclein. J Neurol Neurosurg Psychiatry 2005; 76(4): 596-7.
36. Kruger R, Kuhn W, Muller T, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998; 18(2): 106-8.
37. Zarranz JJ, Alegre J, Gomez-Esteban JC, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004; 55(2): 164-73.
38. Proukakis C, Dudzik CG, Brier T, et al. A novel alpha-synuclein missense mutation in Parkinson disease. Neurology 2013; 80(11): 1062-4.
39. Appel-Cresswell S, Vilarino-Guell C, Encarnacion M, et al. Alpha-synuclein p. H50Q, a novel pathogenic mutation for Parkinson's disease. Mov Disord 2013; 28(6): 811-3.
40. Lesage S, Anheim M, Letournel F, et al. G51D alpha-synuclein mutation causes a novel parkinsonian-pyramidal syndrome. Ann Neurol 2013; 73(4): 459-71.
41. Devine MJ, Gwinn K, Singleton A, Hardy J. Parkinson's disease and alpha-synuclein expression. Mov Disord 2011; 26(12): 2160-8.
42. Singleton AB, Farrer M, Johnson J, et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003; 302(5646): 841.
43. Elia AE, Petrucci S, Fasano A, et al. Alpha-synuclein gene duplication: Marked intrafamilial variability in two novel pedigrees. Mov Disord 2013; 28(6): 813-7.
44. Fuchs J, Nilsson C, Kachergus J, et al. Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology 2007; 68(12): 916-22.
45. Ikeuchi T, Kakita A, Shiga A, et al. Patients homozygous and heterozygous for SNCA duplication in a family with parkinsonism and dementia. Arch Neurol 2008; 65(4): 514-9.
46. Gwinn K, Devine MJ, Jin LW, et al. Clinical features, with video documentation, of the original familial lewy body parkinsonism caused by alpha-synuclein triplication (Iowa kindred). Mov Disord 2011; 26(11): 2134-6.
47. Chartier-Harlin MC, Kachergus J, Roumier C, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004; 364(9440): 1167-9.
48. Ibanez P, Bonnet AM, Debarges B, et al. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 2004; 364(9440): 1169-71.
49. Nishioka K, Hayashi S, Farrer MJ, et al. Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. Ann Neurol 2006; 59(2): 298-309.
50. Nishioka K, Ross OA, Ishii K, et al. Expanding the clinical phenotype of SNCA duplication carriers. Mov Disord 2009; 24(12): 1811-9.
51. Ahn TB, Kim SY, Kim JY, et al. alpha-Synuclein gene duplication is present in sporadic Parkinson disease. Neurology 2008; 70(1): 43-9.
52. Shin CW, Kim HJ, Park SS, Kim SY, Kim JY, Jeon BS. Two Parkinson's disease patients with alpha-synuclein gene duplication and rapid cognitive decline. Mov Disord 2010; 25(7): 957-9.
53. Ross OA, Soto-Ortolaza AI, Heckman MG, et al. Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. Lancet Neurol 2011; 10(10): 898-908.
54. Gasser T, Hardy J, Mizuno Y. Milestones in PD genetics. Mov Disord 2011; 26(6): 1042-8.
55. Bardien S, Lesage S, Brice A, Carr J. Genetic characteristics of leucine-rich repeat kinase 2 (LRRK2) associated Parkinson's disease. Parkinsonism Relat Disord 2011; 17(7): 501-8.
56. Healy DG, Falchi M, O'Sullivan SS, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol 2008; 7(7): 583-90.
57. Vilarino-Guell C, Wider C, Ross OA, et al. VPS35 mutations in Parkinson disease. Am J Hum Genet 2011; 89(1): 162-7.
58. Zimprich A, Benet-Pages A, Struhal W, et al. A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet 2011; 89(1): 168-75.
59. Sheerin UM, Charlesworth G, Bras J, et al. Screening for VPS35 mutations in Parkinson's disease. Neurobiol Aging 2012; 33(4): 838 e1-5.
60. Nuytemans K, Bademci G, Inchausti V, et al. Whole exome sequencing of rare variants in EIF4G1 and VPS35 in Parkinson disease. Neurology 2013; 80(11): 982-9.
61. Sharma M, Ioannidis JP, Aasly JO, et al. A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants. J Med Genet 2012; 49(11): 721-6.
62. Chartier-Harlin MC, Dachsel Jc, Vilarino-Guell C, et al. Translation initiator EIF4G1 mutations in familial Parkinson disease. Am J Hum Genet 2011; 89(3): 398-406.
63. Schulte EC, Mollenhauer B, Zimprich A, et al. Variants in eukaryotic translation initiation factor 4G1 in sporadic Parkinson's disease. Neurogenetics 2012; 13(3): 281-5.
64. Zhao Y, Ho P, Prakash KM, et al. Analysis of EIF4G1 in Parkinson's disease among Asians. Neurobiol Aging 2013; 34(4): 1311 e5-6.
65. Gasser T, Muller-Myhsok B, Wszolek ZK, et al. A susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nat Genet 1998; 18(3): 262-5.
66. DeStefano AL, Lew MF, Golbe LI, et al. PARK3 influences age at onset in Parkinson disease: a genome scan in the GenePD study. Am J Hum Genet 2002; 70(5): 1089-95.
67. Pankratz N, Uniacke SK, Halter CA, et al. Genes influencing Parkinson disease onset: replication of PARK3 and identification of novel loci. Neurology 2004; 62(9): 1616-8.
68. Karamohamed S, DeStefano AL, Wilk JB, et al. A haplotype at the PARK3 locus influences onset age for Parkinson's disease: the GenePD study. Neurology 2003; 61(11): 1557-61.
69. Sharma M, Mueller JC, Zimprich A, et al. The sepiapterin reductase gene region reveals association in the PARK3 locus: analysis of familial and sporadic Parkinson's disease in European populations. J Med Genet 2006; 43(7): 557-62.
70. Leroy E, Boyer R, Auburger G, et al. The ubiquitin pathway in Parkinson's disease. Nature 1998; 395(6701): 451-2.
71. Pankratz N, Nichols WC, Uniacke Sk, et al. Significant linkage of Parkinson disease to chromosome 2q36-37. Am J Hum Genet 2003; 72(4): 1053-7.
72. Lautier C, Goldwurm S, Durr A, et al. Mutations in the GIGYF2 (TNRC15) gene at the PARK11 locus in familial Parkinson disease. Am J Hum Genet 2008; 82(4): 822-33.
73. Tan EK, Schapira AH. Summary of GIGYF2 studies in Parkinson's disease: the burden of proof. Eur J Neurol 2010; 17(2): 175-6.
74. Strauss KM, Martins LM, Plun-Favreau H, et al. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum Mol Genet 2005; 14(15): 2099-111.
75. Ross OA, Soto AI, Vilarino-Guell C, et al. Genetic variation of Omi/HtrA2 and Parkinson's disease. Parkinsonism Relat Disord 2008; 14(7): 539-43.
76. Simon-Sanchez J, Singleton AB. Sequencing analysis of OMI/HTRA2 shows previously reported pathogenic mutations in neurologically normal controls. Hum Mol Genet 2008; 17(13): 1988-93.
77. Socal MP, Emmel VE, Rieder CR, Hilbig A, Saraiva-Pereira ML, Jardim LB. Intrafamilial variability of Parkinson phenotype in SCAs: novel cases due to SCA2 and SCA3 expansions. Parkinsonism Relat Disord 2009; 15(5): 374-8.
78. Hall DA, O'Keefe JA. Fragile x-associated tremor ataxia syndrome: the expanding clinical picture, pathophysiology, epidemiology, and update on treatment. Tremor Other Hyperkinet Mov (N Y). 2012; 2. pii: tre-02-56-352-1.
79. Lesage S, Le Ber I, Condroyer C, et al. C9orf72 repeat expansions are a rare genetic cause of parkinsonism. Brain 2013; 136(Pt 2): 385-91.
80. Hruska kS, LaMarca ME, Scott CR, Sidransky E. Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat 2008; 29(5): 567-83.
81. Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009; 361(17): 1651-61.
82. Wan L, Hsu CM, Tsai CH, Lee CC, Hwu WL, Tsai FJ. Mutation analysis of Gaucher disease patients in Taiwan: high prevalence of the RecNciI and L444P mutations. Blood Cells Mol Dis 2006; 36(3): 422-5.
83. Scott SA, Edelmann L, Liu L, Luo M, Desnick RJ, Kornreich R. Experience with carrier screening and prenatal diagnosis for 16 Ashkenazi Jewish genetic diseases. Hum Mutat 2010; 31(11): 1240-50.
84. Sidransky E. Gaucher disease: complexity in a "simple" disorder. Mol Genet Metab 2004; 83(1-2): 6-15.
85. Neudorfer O, Giladi N, Elstein D, et al. Occurrence of Parkinson's syndrome in type I Gaucher disease. QJM 1996; 89(9): 691-4.
86. Machaczka M, Rucinska M, Skotnicki AB, Jurczak W. Parkinson's syndrome preceding clinical manifestation of Gaucher's disease. Am J Hematol 1999; 61(3): 216-7.
87. Bembi B, Zambito Marsala S, Sidransky E, et al. Gaucher's disease with Parkinson's disease: clinical and pathological aspects. Neurology 2003; 61(1): 99-101.
88. Goker-Alpan O, Schiffmann R, LaMarca ME, Nussbaum RL, McInerney-Leo A, Sidransky E. Parkinsonism among Gaucher disease carriers. J Med Genet 2004; 41(12): 937-40.
89. Halperin A, Elstein D, Zimran A. Increased incidence of Parkinson disease among relatives of patients with Gaucher disease. Blood Cells Mol Dis 2006; 36(3): 426-8.
90. Rana HQ, Balwani M, Bier L, Alcalay RN. Age-specific Parkinson disease risk in GBA mutation carriers: information for genetic counseling. Genet Med 2013; 15(2): 146-9.
91. Anheim M, Elbaz A, Lesage S, et al. Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers. Neurology 2012; 78(6): 417-20.
92. Winder-Rhodes SE, Evans JR, Ban M, et al. Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. Brain 2013; 136(Pt 2): 392-9.
93. Brockmann K, Srulijes K, Hauser AK, et al. GBA-associated PD presents with nonmotor characteristics. Neurology 2011; 77(3): 276-80.
94. Murakami T, Shoji M, Imai Y, et al. Pael-R is accumulated in Lewy bodies of Parkinson's disease. Ann Neurol 2004; 55(3): 439-42.
95. Gegg ME, Burke D, Heales SJ, et al. Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann Neurol 2012; 72(3): 455-63.
96. Mazzulli JR, Xu YH, Sun Y, et al. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011; 146(1): 37-52.
97. Bender A, Krishnan KJ, Morris CM, et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nat Genet 2006; 38(5): 515-7.
98. Finsterer J. Parkinson's syndrome and Parkinson's disease in mitochondrial disorders. Mov Disord 2011; 26(5): 784-91.
99. Orsucci D, Caldarazzo Ienco E, Mancuso M, Siciliano G. POLG1-related and other "mitochondrial Parkinsonisms": an overview. J Mol Neurosci 2011; 44(1): 17-24.
100. Baloh RH, Salavaggione E, Milbrandt J, Pestronk A. Familial parkinsonism and ophthalmoplegia from a mutation in the mitochondrial DNA helicase twinkle. Arch Neurol 2007; 64(7): 998-1000.
101. Mancuso M, Filosto M, Orsucci D, Siciliano G. Mitochondrial DNA sequence variation and neurodegeneration. Hum Genomics 2008; 3(1): 71-8.
102. Hudson G, Nalls M, Evans JR, et al. Two-stage association study and meta-analysis of mitochondrial DNA variants in Parkinson disease. Neurology 2013; 80(22): 2042-8.
103. Corti O, Lesage S, Brice A. What genetics tells us about the causes and mechanisms of Parkinson's disease. Physiol Rev 2011; 91(4): 1161-218.
104. Klein C, Lohmann-Hedrich K, Rogaeva E, Schlossmacher MG, Lang AE. Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol 2007; 6(7): 652-62.
105. Marongiu R, Ferraris A, Ialongo T, et al. PINK1 heterozygous rare variants: prevalence, significance and phenotypic spectrum. Hum Mutat 2008; 29(4): 565.
106. Bruggemann N, Mitterer M, Lanthaler AJ, et al. Frequency of heterozygous Parkin mutations in healthy subjects: need for careful prospective follow-up examination of mutation carriers. Parkinsonism Relat Disord 2009; 15(6): 425-9.
107. Maraganore DM, de Andrade M, Elbaz A, et al. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA 2006; 296(6): 661-70.
108. Mata IF, Shi M, Agarwal P, et al. SNCA variant associated with Parkinson disease and plasma alpha-synuclein level. Arch Neurol 2010; 67(11): 1350-6.
109. Tan EK. The role of common genetic risk variants in Parkinson disease. Clin Genet 2007; 72(5): 387-93.
110. Sharma M, Ioannidis JP, Aasly JO, et al. Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology 2012; 79(7): 659-67.
111. Lill CM, Roehr JT, McQueen MB, et al. Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database. PLoS Genet 2012; 8(3): e1002548.
112. Pankratz N, Beecham GW, DeStefano AL, et al. Metaanalysis of Parkinson's disease: identification of a novel locus, RIT2. Ann Neurol 2012; 71(3): 370-84.